6-氟-2,3-二氢-2,2-二甲基色烯-4-酮 | 105799-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 6-氟-2,3-二氢-2,2-二甲基色烯-4-酮
• 英文名称: 6-fluoro-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-one
• 英文别名: 6-fluoro-2,2-dimethyl-chroman-4-one；6-fluoro-2,2-dimethyl-4-chromanone；6-Fluoro-2,2-dimethylchroman-4-one；6-fluoro-2,2-dimethyl-3H-chromen-4-one
• CAS: 105799-73-3
• 化学式: C₁₁H₁₁FO₂
• 分子量: 194.206
• InChiKey: MPJMDEXLUJRBBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  282.6±40.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-氟-2,3-二氢-2,2-二甲基色烯-4-酮 在 盐酸 、 sodium tetrahydroborate 、 硫酸 作用下， 以 甲醇 为溶剂， 生成 4-amino-3,4-dihydro-2,2-dimethyl-6-fluoro-(2H)-1-benzopyran
  参考文献：
  名称：

  4,6-Disubstituted 2,2-Dimethylchromans Structurally Related to the K_ATP Channel Opener Cromakalim: Design, Synthesis, and Effect on Insulin Release and Vascular Tone

  摘要：

  Five series (ureas, thioureas, carbamates, sulfonylureas, and amides) of 4,6-disubstituted-2,2dimethylchromans structurally related to cromakalim were prepared and evaluated, as putative ATP-sensitive potassium channel activators, on rat pancreatic islets and rat aorta rings. The biological data indicate that most compounds were, like the reference molecule cromakalim, more active on the vascular smooth muscle tissue (myorelaxant effect on 30 mM KCl induced contractions of rat aorta rings) than on the pancreatic tissue (inhibition of 16.7 mM glucose induced insulin release from rat pancreatic islets). However, some drugs (8h, 8i, 9f, 9g, 9h, and 9i) markedly inhibited insulin release and exhibited an activity equivalent or greater than that of diazoxide. Compounds 9h and 9i were also found to be more active on pancreatic beta-cells than on vascular smooth muscle cells. Last, the amide 6b was selected in order to examine its mechanism of action on vascular smooth muscle cells. Pharmacological results suggest that the compound acted as a K-ATP channel opener. In conclusion, the present data indicate that appropriate structural modifications can generate dimethylchromans with pharmacological profiles different from that of cromakalim.

  DOI：

  10.1021/jm040789e
• 作为产物：
  描述：

  4-氟苯基醋酸酯 在 四氢吡咯 、 aluminum (III) chloride 、 乙酰氯 作用下， 以 甲醇 为溶剂， 生成 6-氟-2,3-二氢-2,2-二甲基色烯-4-酮
  参考文献：
  名称：

  氟化和非氟化4-苯基(硫代)脲基取代2,2-二甲基色满作为胰岛素释放抑制剂和平滑肌松弛剂的研究进展

  摘要：

  目的：本研究旨在表征氟原子在4-苯基（硫）脲基取代的2,2-二甲基色酮的苯基和苯并吡喃环上的存在或缺失对其抑制胰岛素释放或放松血管平滑肌细胞能力的影响。 方法：大多数化合物被发现能抑制胰岛素分泌并引起明显的肌松活性。 结果：在2,2-二甲基色酮核心结构的6位缺乏氟或氯原子会降低对胰岛内分泌组织的抑制活性。在两种组织中最活跃的化合物之一，化合物11h（BPDZ 678），被选为进一步的药理学研究对象。 结论：生物学数据表明，11h主要表现为胰岛β细胞上的KATP通道开放剂，尽管还观察到钙离子进入阻断效应。在血管平滑肌细胞上，11h表现为钙离子进入阻滞剂。

  DOI：

  10.2174/1573406418666220221145500

文献信息

• Catalytic C–C coupling of diazo compounds with arylboronic acids: using surface modified sewage sludge as catalyst
  作者：Zhipeng Zhang、Yang Yu、Yuxing Xie、Timothy Hughes、Jun Xu、Fei Huang、He Huang

  DOI：10.1039/d0gc00317d

  日期：——

  carbonaceous materials (SW) by perchloric acid catalyzed coupling reactions between diazo compounds and arylboronic acids was developed. The reaction shows a high level of functional tolerance and a broad substrate scope. Furthermore, the highly selective 1,2-alkyl shift products were furnished through the sterically demanding R4, R5 migration of diazo compounds (3-diazochromanone). The structures of 1,2-shift

  通过高氯酸催化重氮化合物与芳基硼酸之间的偶联反应，开发了一种绿色，温和且高效的合成方法，该方法利用污水污泥衍生的碳质材料（SW）合成二芳基次甲基。该反应显示出高水平的功能耐受性和广泛的底物范围。此外，通过空间要求高的R 4，R 5提供了高选择性的1,2-烷基转移产物重氮化合物（3-重氮苯并二氢吡喃酮）的迁移。通过单晶X射线分析进一步证实了1，2-移位产物的结构。值得注意的是，darifenacin（一种用于膀胱过度活动症的临床药物，OAB）和diclofensine（一种显示出抗抑郁和单胺再摄取抑制剂活性的兴奋剂）的核心结构的合成进一步证明了该方法的有效性和合成潜力。
• Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors
  作者：Christopher A. Lipinski、Charles E. Aldinger、Thomas A. Beyer、Jon Bordner、Douglas F. Burdi、Donald L. Bussolotti、Philip B. Inskeep、Todd W. Siegel

  DOI：10.1021/jm00090a004

  日期：1992.6

  The hypothesis that clinical side effects of the aldose reductase inhibitor (ARI) sorbinil were related to its hydantoin ring led to a bioisosteric analysis and replacement of the hydantoin by a spiro hydroxy acetic acid moiety as in 40. These hydroxy acids, compared to hydantoins, showed a similar potency increase on chroman 2-methyl substitution, a similar orthogonal relationship of acidic to aromatic

  醛糖还原酶抑制剂（ARI）山梨醇的临床副作用与其乙内酰脲环有关的假说导致了生物立体分析并用螺羟基乙酸部分取代乙内酰脲，如40所示。与乙内酰脲相比，这些羟酸在苯并二氢吡喃2-甲基取代时，效价增加相似，酸性与芳族部分的正交关系相似，ARI对映选择性也相似。在该系列中，六元螺羟基乙酸乙酸阴离子阵列是螺乙内酰脲阴离子的生物等排体，可导致ARI具有出色的体内活性。像第4步那样，通过苯并二氢吡喃-2-甲基化和通过芳香族6,7-卤素取代，使体外和体内活性提高了40倍以上。将大鼠体内具有最佳急性体内活性的化合物的慢性体内活性进行了比较。
• Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
  申请人：Hoechst Aktiengesellschaft

  公开号：US06191164B1

  公开（公告）日：2001-02-20

  Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or a diagnostic, and medicament comprising them Chromans of the formula I and of the formula 1a having the meanings R(A), R(B), R(C) and R(1) to R(8) indicated in the claims are outstandingly suitable for preparing a medicament for blocking the K+ channel which is opened by cyclic adenosine monophosphate (cAMP); and further for preparing a medicament for inhibiting gastric acid secretion; for the treatment of ulcers of the stomach and of the intestinal region, in particular of the duodenum, for the treatment of reflux esophagitis, for the treatment of diarrheal illnesses, for the treatment and prevention of all types of arrhythmias including ventricular and supraventricular arrhythmias, and for the control of reentry arrhythmias and for the prevention of sudden heart death as a result of ventricular fibrillation.

  磺胺基取代的色苷，其制备方法，其用作药物或诊断的用途，以及包含它们的药物 具有下式I的色苷和下式1a的色苷，其中在权利要求中指示的R(A)、R(B)、R(C)和R(1)到R(8)的含义，非常适合制备用于阻断由环磷酸腺苷单磷酸（cAMP）打开的K+通道的药物；进一步用于制备用于抑制胃酸分泌的药物；用于治疗胃和肠道溃疡，特别是十二指肠的药物；用于治疗反流性食道炎；用于治疗腹泻疾病；用于治疗和预防包括室性和房性心律失常在内的所有类型心律失常；用于控制再入性心律失常和预防由室颤引起的突发心脏死亡。
• [EN] TRPV1 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV1
  申请人：ABBOTT LAB

  公开号：WO2010045401A1

  公开（公告）日：2010-04-22

  Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文披露了式（I）的化合物，或其药用可接受的盐、溶剂化合物、前药、前药的盐或它们的组合，其中R1、R2、R3、R4和m在规范中有定义。还披露了包含这种化合物的组合物以及使用这种化合物和组合物治疗疾病和疾病的方法。
• Sulfonamide-substituted chromans, processes for their preparation, their
  申请人：Hoechst Marion Roussel Deutschland

  公开号：US05955607A1

  公开（公告）日：1999-09-21

  Compounds of the formula I ##STR1## having the meanings of the substituents indicated in the claims are outstandingly efficacious substances for producing medicaments for the prophylaxis and for the therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastrointestinal region or for the treatment of diarrheal disorders.

  具有公式I ##STR1## 的化合物，其在索赔中指示的取代基的含义是用于生产预防和治疗心血管疾病，特别是心律失常，治疗胃肠道溃疡或腹泻疾病的药物的非常有效的物质。